BioVie Inc will present results from two Phase 2 trials of its experimental drug bezisterim for Long COVID and Parkinson's disease at the American Neurological Association meeting in San Diego from October 17 to 20. The trials showed promising improvements in inflammation markers, neuronal health, and symptoms such as brain fog, fatigue, and motor function. Bezisterim is an oral drug that crosses the blood-brain barrier and aims to reduce inflammation without suppressing the immune system. These results could advance treatment options for chronic neurological conditions and follow BioVie's ongoing research in Alzheimer's disease.
BioVie’s upcoming presentation on Long COVID and Parkinson’s trial results provides context for health sector activity. For readers following the health sector, here is Pluang's market snapshot as of Oct 14, 2026 20:11 WIB: out of 150 priced US health stocks, 73 rose and 68 fell. Notable movers include BNGO at USD 1.39 with a 1.84% gain and a typical hold time of 50 days, HIMS at USD 29.20 down 1.72%, and BKD at USD 10.29 up 1.63%.
Atlas Energy Corp. completed its first royalty acquisition for $15 million on producing oil and gas assets in Southwest Alberta, funded by cash. The company began generating royalty revenue immediately, earning $141,000 in just seven days post-acquis...
AELO Swiss Academy has transformed into an international airline pilot training organization with bases in Locarno, Lugano, and Cuneo, reflecting over 40 years of aviation heritage. The academy reported a 186% increase in operations in September 2026...
Stantec Inc. reported a 9.4% increase in net revenue to $1.9 billion for Q3 2026, driven by organic and acquisition growth. Adjusted EBITDA rose 16.6% to $377.1 million with a record margin of 20.2%, while adjusted EPS grew 23.5% to $1.89. The compan...
Super League Enterprise, a company specializing in audience intelligence and media activation for the gaming industry, announced it will release its financial results for the third quarter ending September 30, 2026, on November 16, 2026, after market...
Reviva Pharmaceuticals announced it expects FDA feedback in Q4 2026 on a new formulation of brilaroxazine for its RECOVER-2 Phase 3 trial targeting schizophrenia. The company plans to start a bioequivalence study in Q1 2027 and begin patient enrollme...
